Unexpected Long‐Term Disease Control in Lung Cancer With Sacral Metastases After Conventional Radiotherapy and Chemotherapy Despite Discontinuation of Maintenance Therapy: A Case Report

Novel treatments, including stereotactic body radiotherapy (SBRT), targeted therapies, and immune checkpoint inhibitors (ICIs), have improved the prognosis and outcomes of patients with metastatic lung cancer. However, not all patients are eligible for these treatments; furthermore, these novel therapies are not readily available in developing countries. We report a 54-year-old man who presented with a sacral mass, initially suspected as a chordoma and underwent subtotal resection. Further evaluation revealed a mass in the lung, confirming the pulmonary origin of the tumor. He received palliative radiotherapy (RT) to the residual sacral lesion, chemotherapy with bevacizumab, and 3D-RT to a lung lesion. Bevacizumab was discontinued after one year of maintenance therapy following a serious gastrointestinal perforation. Surprisingly, two years after stopping all treatment, he has had no sign of disease progression.